Subscribe to Search results

At the meeting between Rorer Healthcare and the DHSS they discussed two cases of seroconversion and discussed if they could hold it from breaking into the public domain for a little longer. They said Dr Hill did not intend to disclose the cases to the haemophilia centre directors unless it was absolutely essential but would have to inform the parents of the children.

Published on:

In a letter from Armour Dr P Harris stated that it should not be overlooked that there may be material in centres or in patients' homes that was not derived from donors tested for anti HTLV-III.

Published on:

In a memo, Dr Harris discussed his conversation with Dr Jones who told him that he did not wish to receive replacement material since it was his belief that their (Armour's) material was less safe in the hepatitis risk area. Dr Jones asked for the letter and this call to be confidential as he had recently had "his wrists slapped for public statements".

Published on:

In a letter to blood banks directors and haemophilia treatment centre coordinators Armour recommended that lots of HT Factorate concentrates derived from non-tested plasma should not be used and that they would arrange for centres to exchange any inventory of product manufactured from untested plasma at no cost to the centres.

Published on:

In response to the media response on AIDS fears prompting recall of blood products Christopher Bishop said that Armour should treat media articles with the contempt they deserved and that they could not make a statement on reviewing the current heat process because they couldn't defend existing treatment and immediately introduce a new one.

Published on:

In a memo Christopher Bishop advised colleagues on responses to be used with regards to queries about them reviewing their heat treatment procedure and said they had a considerable quantity of existing material and they wouldn't want people to hold off ordering until the new product came through.

Published on:

In a memo regarding the seroconversion of two children with haemophilia who had received Armour heat-treated product Robert Christie said Dr Harris had reported the findings in broad outline to the DHSS and promised to supply more information following a written report from Dr Hill. Robert Christie said he agreed that the incident should be reported to the DHSS and a publication describing Dr Hill's experience prepared.

Published on:

In a memo regarding the seroconversion of two children with haemophilia who had received Armour heat treated product Robert Christie said Dr Harris had reported the findings in broad outline to DHSS and promised to supply more information following a written report from Dr Hill

Published on:

Dr Jeffreys Chief Medical Officer said further to the call with Dr Rotblatt they would need to visit the DHSS the next day before the weekend and that Armour would probably be "no doubt looking at voluntarily withdrawing the product on Monday".

Published on:

Armour's Factorate was removed from the market and two of its product licenses relinquished following consultation with the DHSS after two seroconversion cases of AIDS from heat treated Factorate.

Published on:

In a letter to Dr Rotblat, Dr Christie reported the second case of seroconversion following the use of heat-treated Armour Factorate.

Published on:

Dr Harris in a letter to Dr Colvin stated that each donation was now screened for HTLV-3 but that they recognised old material may be in centres and any decision to give patients information about this potentially distressing information rested with Dr Colvin as the unit director.

Published on:

The "Morbidity and Mortality Weekly Report" stated that the Medical and Scientific Advisory Council of the National Hemophilia Foundation recently issued revised recommendations for haemophilia therapy which included that the use of non-heat-treated factor concentrates should be limited.

Published on:

The "Morbidity and Mortality Weekly Report" included figures from Cutter which showed that their heat treatment process had inactivated HTLV-3 virus to a degree that the virus was undetectable after 24 hours of heat treatment.

Published on:

The Medical and Scientific Advisory Council of the US National Hemophilia Foundation endorsed the use of heat-treated products. The CDC endorsed the use of heat treatment. It carried out the viral inactivation studies on infectious particles in cooperation with Cutter Laboratories.

Published on:

Gilbert C et al published an article in "The Lancet" describing a case of seroconversion of AIDS in a person with mild haemophilia after administration of high doses of heat-treated Factor 8 concentrate.

Published on:

An article by Robert J Gerety and Lewellys F Barker described viral inactivation as one of the measures of interest since 1975 undertaken with hopes of increasing safety of haemophiliacs from HBV.

Published on:

A paper discussed Cutter continuing to carry out studies in the hope of finding ways in which Konyne product may be rendered non-infective.

Published on:

Horowitz et al discussed their viral inactivation study in this paper which was later put into production by the New York Blood Centre.

Published on:

A memo from Linda Frith showed the total volume of returned regular material and total sales of Koate, and that for a short period of time Cutter would take a share of the NHS Factor 8 market.

Published on: